N@N

Blockbuster weight-loss drugs linked to lower risk of addiction, schizophrenia, dementia, and more

The article from MSN discusses a study linking blockbuster weight loss drugs like Ozempic and Wegovy, which contain the active ingredient semaglutide, to a reduced risk of various mental health and neurological conditions. According to the research, these medications, originally developed for diabetes management, have shown potential in decreasing the likelihood of developing conditions such as addiction, schizophrenia, and dementia. The study suggests that semaglutide might influence brain functions related to reward and cognitive processes, potentially due to its action on the GLP-1 receptor, which could explain the observed benefits. However, the article also notes that while these findings are promising, more research is needed to confirm these effects and understand the underlying mechanisms fully. The drugs are part of a class known as GLP-1 agonists, which mimic an incretin hormone that stimulates insulin secretion in response to meals.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/health/weightloss/blockbuster-weight-loss-drugs-linked-to-lower-risk-of-addiction-schizophrenia-dementia-and-more/ar-AA1xwWje ]